Nicolette Sherman - Certara Chief Officer
| CERT Stock | USD 11.21 0.06 0.53% |
Insider
Nicolette Sherman is Chief Officer of Certara
| Age | 54 |
| Address | 100 Overlook Center, Princeton, NJ, United States, 08540 |
| Phone | 609 716 7900 |
| Web | https://www.certara.com |
Nicolette Sherman Latest Insider Activity
Tracking and analyzing the buying and selling activities of Nicolette Sherman against Certara stock is an integral part of due diligence when investing in Certara. Nicolette Sherman insider activity provides valuable insight into whether Certara is net buyers or sellers over its current business cycle. Note, Certara insiders must abide by specific rules, including filing SEC forms every time they buy or sell Certara'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Nicolette Sherman over a year ago Payment of 1057 shares by Nicolette Sherman of Certara subject to Rule 16b-3 | ||
Nicolette Sherman over a year ago Exercise or conversion by Nicolette Sherman of 90 shares of Certara subject to Rule 16b-3 |
Certara Management Efficiency
Return On Tangible Assets is likely to drop to -0.16 in 2024. Return On Capital Employed is likely to gain to -0.03 in 2024. Total Current Liabilities is likely to drop to about 97 M in 2024. Liabilities And Stockholders Equity is likely to drop to about 1.5 B in 2024Certara's management efficiency ratios could be used to measure how well Certara manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Jon Boumstein | National Research Corp | N/A | |
| Aammaad Shams | Evolent Health | 40 | |
| Craig Barbarosh | Evolent Health | 52 | |
| Jason Jones | Health Catalyst | N/A | |
| Matthew Morris | Privia Health Group | 60 | |
| Peter Grua | Evolent Health | 66 | |
| Tunde Sotunde | Evolent Health | N/A | |
| Dave Ross | Health Catalyst | N/A | |
| Jason Alger | Health Catalyst | 40 | |
| M Duffy | Evolent Health | 61 | |
| Teresa McMeans | CareMax | N/A | |
| Paul Horstmeier | Health Catalyst | 63 | |
| Tyson Murdock | HealthEquity | 53 | |
| Kevin Wirges | CareMax | 44 | |
| Niberto MD | CareMax | N/A | |
| CPA CPA | National Research Corp | 66 | |
| Helen Hrdy | National Research Corp | 59 | |
| Carlos Solo | CareMax | 45 | |
| Regla Wuilchrist | CareMax | N/A | |
| Gregory MS | National Research Corp | N/A | |
| Kali Beyah | Evolent Health | N/A | |
Management Performance
| Return On Equity | -0.0295 | ||||
| Return On Asset | 0.0059 |
Certara Leadership Team
Elected by the shareholders, the Certara's board of directors comprises two types of representatives: Certara inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Certara. The board's role is to monitor Certara's management team and ensure that shareholders' interests are well served. Certara's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Certara's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Richard Traynor, General VP | ||
| Frederic Bois, Head Advisor | ||
| Robert Aspbury, President Software | ||
| Sheila MBA, Chief Officer | ||
| Ron DiSantis, Senior Development | ||
| Patrick PharmD, President Solutions | ||
| William Feehery, CEO Director | ||
| John III, Chief Officer | ||
| Max Kanevsky, Chief Officer | ||
| Andrew Schemick, Chief Officer | ||
| Rona Anhalt, Chief Officer | ||
| Nicolette Sherman, Chief Officer | ||
| Jaap Mandema, Chief Officer | ||
| Leif Pedersen, President Officer | ||
| Daniel Corcoran, Chief Counsel |
Certara Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Certara a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0295 | ||||
| Return On Asset | 0.0059 | ||||
| Profit Margin | (0.08) % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 1.88 B | ||||
| Shares Outstanding | 160.98 M | ||||
| Shares Owned By Insiders | 2.59 % | ||||
| Shares Owned By Institutions | 95.94 % | ||||
| Number Of Shares Shorted | 4.96 M | ||||
| Price To Book | 1.71 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Certara Stock Analysis
When running Certara's price analysis, check to measure Certara's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Certara is operating at the current time. Most of Certara's value examination focuses on studying past and present price action to predict the probability of Certara's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Certara's price. Additionally, you may evaluate how the addition of Certara to your portfolios can decrease your overall portfolio volatility.